Real-World Effectiveness and Safety of Tildrakizumab in Moderate-to-Severe Psoriasis: A Multicenter Experience in the Basque Country
Tildrakizumab demonstrated high effectiveness and a favorable safety profile in this large, real-world multicenter cohort. These findings support its role as a reliable therapeutic option for patients with moderate-to-severe plaque psoriasis in clinical practice.
Authors
- Mikel Meruelo-Ruano
- Itziar Arrúe-Michelena
- R. González‐Pérez (ORCID: https://orcid.org/0000-0001-5238-215X)
- Isabel Gainza-Apraiz
- R. Izu (ORCID: https://orcid.org/0000-0001-6159-6395)
- Ana Martínez de Salinas Quintana
- Belen Navajas-Pinedo
- Ana Orbea-Sopeña
- Irene Arevalo-Ortega
- Ana Martínez-Buil
- Gadea Braceras-Rincón
- Begoña Ramos-Bareño
- Manuel Pascual-Ares
Institutions
- Federal Urdu University (PK)
- BioCruces Health research Institute (ES)
- Hospital de Basurto (ES)
- Biogipuzkoa Health Research Institute (ES)
- Hospital Universitario Araba (ES)
- Hospital de Cruces (ES)
- Donostiako Unibertsitate Ospitalea (ES)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1007/s13555-025-01607-8
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00